93 related articles for article (PubMed ID: 18502842)
1. Lenalidomide: what is the right dose in CLL?
Lin TS
Blood; 2008 Jun; 111(11):5268. PubMed ID: 18502842
[No Abstract] [Full Text] [Related]
2. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Nelde A; Kowalewski DJ; Backert L; Schuster H; Werner JO; Klein R; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S; Walz JS
Oncoimmunology; 2018; 7(4):e1316438. PubMed ID: 29632711
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
Chen CI; Paul H; Snitzler S; Kakar S; Le LW; Wei EN; Lau A; Johnston JB; Gibson SB; Queau M; Spaner D; Croucher D; Sherry B; Trudel S
Leuk Lymphoma; 2019 Apr; 60(4):980-989. PubMed ID: 30277089
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
6. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.
Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Exp Hematol; 2014 Feb; 42(2):126-36.e1. PubMed ID: 24212063
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Hughes JH; Phelps MA; Upton RN; Reuter SE; Gao Y; Byrd JC; Grever MR; Hofmeister CC; Marcucci G; Blum W; Blum KA; Foster DJR
Br J Clin Pharmacol; 2019 May; 85(5):924-934. PubMed ID: 30672004
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Strati P; Takahashi K; Peterson CB; Keating MJ; Thompson PA; Daver NG; Jain N; Burger JA; Estrov Z; O'Brien SM; Kantarjian HM; Wierda WG; Futreal PA; Ferrajoli A
Blood Adv; 2019 May; 3(9):1533-1539. PubMed ID: 31076409
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.
Shaim H; Estrov Z; Harris D; Hernandez Sanabria M; Liu Z; Ruvolo P; Thompson PA; Ferrajoli A; Daher M; Burger J; Muftuoglu M; Imahashi N; Li L; Liu E; Alsuliman AS; Basar R; Nassif Kerbauy L; Sobieski C; Gokdemir E; Kondo K; Wierda W; Keating M; Shpall EJ; Rezvani K
Front Immunol; 2017; 8():1773. PubMed ID: 29379494
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
13. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
Soumerai JD; Davids MS; Werner L; Fisher DC; Armand P; Amrein PC; Neuberg D; Hochberg EP; Brown JR; Abramson JS
Leuk Lymphoma; 2019 Dec; 60(12):2931-2938. PubMed ID: 31074316
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
16. Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies.
Blumel S; Broadway-Duren J
J Adv Pract Oncol; 2014; 5(4):269-79. PubMed ID: 26110071
[TBL] [Abstract][Full Text] [Related]
17. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Ujjani C; Wang H; Skarbnik A; Trivedi N; Ramzi P; Khan N; Cheson BD
Blood Adv; 2018 Apr; 2(7):762-768. PubMed ID: 29610115
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
Wendtner CM; Hallek M; Fraser GA; Michallet AS; Hillmen P; Dürig J; Kalaycio M; Gribben JG; Stilgenbauer S; Buhler A; Kipps TJ; Purse B; Zhang J; De Bedout S; Mei J; Chanan-Khan A
Leuk Lymphoma; 2016; 57(6):1291-9. PubMed ID: 26763349
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]